Pfizer files NDA for Sutent

Pfizer has filed an NDA for Sutent, a potent new multi-kinase inhibitor that may have broad uses in the fight against cancer. The drug giant's NDA is focused on gaining FDA approval for Sutent as a tool to fight malignant gastrointestinal stromal tumor and metastatic renal cell carcinoma among patients whose tumors do not respond to or do not tolerate standard treatment options. But researchers believe that the way the drug works -- starving tumors of a supply of blood through a protein inhibitor -- may make it effective against breast, lung, prostate, and colorectal cancers.

- read this press release for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.